

Real World Evidence Study of SYN023 in Children Exposed to Rabies

NCT07327307

Status	RECRUITING
Sponsor	Synermore Biologics (Suzhou) Co., Ltd.
Enrollment	232 participants

Key Eligibility Criteria

Inclusion (5)

- Age under 18 years on the day of enrollment, regardless of gender, and able to provide legal proof of identity;
- Individuals with WHO Category III rabies exposure, and the time from exposure to the initiation of Post-Exposure Prophylaxis (PEP) is ≤ 7 days;
- Have completed standardized wound management, injection of Zamerovimab and Mazorelvimab Injection /other passive immunization products, and the first dose of rabies vaccination within 24 hours prior to screening;
- The volunteer's guardian voluntarily agrees to their participation in the study and signs the informed consent form. Specifically: for volunteers under 8 years old, the guardian signs the informed consent form with the child's assent fully respected; for volunteers aged 8-17, the guardian signs the informed consent form, and the minor volunteer signs the minor assent form;
- Willing and able to comply with all study procedures, and is expected to be able to complete the full course of rabies vaccination and the 1-year follow-up as required (with no plans for long-term absence or relocation from the study area).

Exclusion (2)

- Based on inquiry, besides the current Category III rabies exposure, there is a history of bites by dogs, cats, mongooses, foxes, ferrets, skunks, bats, or raccoons within the past year;
- Other conditions considered by the investigator as unsuitable for participation in this study.

Locations (6 total)

Peking University First Hospital, Beijing, Beijing Municipality, China
Shenzhen second people's hospital, Shenzhen, Guangdong, China
The University of Hong Kong - Shenzhen Hospital, Shenzhen, Guangdong, China
... and 3 more locations